Barely Significant
← all excerpts

Laquinimod in the treatment of multiple sclerosis: a review of the data so far.

Drug Des Devel Ther · 2016 · PMC4798201 · PMID 27042003

Europe PMCDOI
1
hedged sentence
0.0498
closest p · 1.0× alpha
0.0498
boldest claim

The sentences

marginally significantP =0.0498actually significant
Patients receiving laquinimod 0.3 mg/day displayed a marginally significant 44% reduction of the mean cumulative number of GdE MRI lesions compared with placebo ( P =0.0498).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.